PBM inhibited the TLR4/MyD88/NF-κB signaling cascade, reducing the expression of inflammatory genes.
It also suppressed activation of the NLRP3 inflammasome (ASC, caspase-1), lowering the production of IL-1β and IL-18.
Consequently, pro-inflammatory cytokines (TNF-α, IL-6, IL-17) decreased, while anti-inflammatory mediators (IL-10, TGF-β) increased.
ROS accumulation in joint tissues was markedly reduced, alleviating oxidative stress.